Seeking Alpha report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Why MDLN Stock advanced +0.38% Today — RQD Quant Desk Flash
Medline Inc. (MDLN) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MDLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Medline Inc. (NASDAQ: MDLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $32.12 (+0.38% 1D, market cap $42.07B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, MDLN ranks #422 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MDLN compare to RMD and BDX in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), MDLN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 8.2%. By comparison, RMD (ResMed Inc.) holds a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B) and BDX (Becton Dickinson and Company) posts a C+ grade (67/100 RQD, P/E 32.2x, ROIC 4.9%, cap $54.03B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MDLN?
▼
Per MDLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002046386), Medline Inc. generated $28.43B in revenue (+11.5% YoY), $1.16T in net income, and $1.30B in free cash flow against $38.48B in total assets and $12.48B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 2.50 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 5/9
SEC Form 4 / 13F Thermometer: 55% Net Buy • Cannibal Buyback (-0.96% YoY Shares)
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a MDLN Turnaround Squeeze
While MDLN currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($34.41) and Max Pain ($33.73) forces dealer call-delta covering toward $53.42.
Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.96% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why MDLN Stock advanced +0.38% Today — RQD Quant Desk Flash
Medline Inc. (MDLN) advanced +0.38% to $32.12, trading at 4% of its 52-week range ($31.37 – $50.88). Stretched risk/reward at current multiples (8% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 4% of its 52-week range ($31.37 – $50.88) with RSI-14 at 30.9 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.2% around $32.12 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 26.4% gross margin and $1.3B annual free cash flow.
Investing.com report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
https://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-medline-removes-or-corrects-all-medline-brand-beds-and-accessories
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MDLN)
- ✓Walkthrough of MDLN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
MDLN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +11.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MDLN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MDLN. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MDLN)
1. Head-to-Head Health Care Peer Comparison (MDLN vs. RMD, BDX, DXCM, WST)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Medline Inc. (MDLN) ranks #422 by composite RQD confidence (44/100, grade D) and #46 by equity capitalization ($42.07B). Within this direct 5-issuer industry benchmark cohort, RMD leads on earnings valuation at 25.4x trailing P/E, while RMD leads on capital efficiency and profitability with 22.9% ROIC and 59.4% gross margin. RMD currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with MDLN at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MDLN
ACTIVE
Medline Inc. | D | 44/100 | — | — | 8.2% | +0.38% | $42.07B | Benchmark Subject |
| RMD ResMed Inc. | A | 86/100 | 25.4x | 59.4% | 22.9% | -9.05% | $35.56B | /rmd-vs-mdln → |
| BDX Becton Dickinson and Company | C+ | 67/100 | 32.2x | 45.4% | 4.9% | -0.23% | $54.03B | /bdx-vs-mdln → |
| DXCM DexCom Inc. | B+ | 76/100 | 36.1x | 60.1% | 21.6% | +2.95% | $30.16B | /dxcm-vs-mdln → |
| WST West Pharmaceutical Services Inc. | A- | 81/100 | 59.4x | 35.9% | 17.9% | -0.97% | $29.32B | /wst-vs-mdln → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002046386In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medline Inc. (MDLN) reported GAAP revenue of $28.43B (+11.5% vs. FY2024 revenue of $25.51B , and +22.4% cumulative change since FY2023) , GAAP net income of $1.16T, operating cash flow of $1.74B, and free cash flow of $1.30B (-8.3% YoY). On the balance sheet, MDLN closed FY2025 with $38.48B in total assets against $12.48B in total debt (Altman Z-Score: 2.50, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $28.43B | $1.16T | $1.74B | $1.30B | $38.48B | $12.48B |
| FY2024 (FY) | 2024-12-31 | $25.51B | $0 | $1.77B | $1.42B | $35.98B | $16.42B |
| FY2023 (FY) | 2023-12-31 | $23.23B | $0 | $1.69B | $639.6M | $27.88B | $6.52B |
3. MDLN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MDLN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Medline Inc. (NASDAQ: MDLN) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $32.12 (+0.38% 1D, market cap $42.07B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 11/20. Across 1016 tracked Health Care issuers, MDLN ranks #422 in composite RQD confidence.
How does MDLN compare to RMD and BDX in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), MDLN carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 8.2%. By comparison, RMD (ResMed Inc.) holds a A grade (86/100 RQD, P/E 25.4x, ROIC 22.9%, cap $35.56B) and BDX (Becton Dickinson and Company) posts a C+ grade (67/100 RQD, P/E 32.2x, ROIC 4.9%, cap $54.03B). Among the 5-stock peer group, RMD leads on earnings multiple (25.4x) while RMD leads on capital efficiency (22.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MDLN?
Per MDLN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002046386), Medline Inc. generated $28.43B in revenue (+11.5% YoY), $1.16T in net income, and $1.30B in free cash flow against $38.48B in total assets and $12.48B in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MDLN trading relative to its 50-day, 200-day, and 52-week technical levels?
MDLN last traded at $32.12 (+0.38% on volume of 14,573,471 shares), positioning the stock -6.66% below its 50-day simple moving average ($34.41) and -18.75% below its 200-day simple moving average ($39.53). Across its 52-week range of $31.37 to $50.88, MDLN sits at the 3.8% percentile with a 14-day RSI of 30.9 (OVERSOLD (<32)) and an implied next-earnings move of ±6.2% ($30.13 to $34.11).
MDLN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MDLN stock moving today?
Why MDLN Stock advanced +0.38% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (8% return on capital) under elevated 10-year interest-rate pressure.
MDLN — Medline Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, MDLN scores 44 out of 100, earning a D grade and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC 8.2%; FCF yield 3.08%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 11/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (Beta 1.11; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 2.5; Piotroski F 5/9; Debt/Equity 1.16).
Taken together, the pillars indicate weak scores across cash generation, institutional flow, and macro fit, with the balance sheet scoring highest of the five but still below half of its weight. For a prospective investor evaluating the stock today, the rating points to a limited set of upside drivers in the source data and a cautionary posture on the rating's own terms. The 3.08% FCF yield and 8.2% ROIC are the figures the rating cites as the core cash-engine evidence; the 1.11 beta indicates above-market sensitivity to broad moves, and the rating treats that as a macro-fit weakness. The valuation tradeoff is visible in the EV/EBITDA of 20.3 set against the 7.8% operating margin: the source data does not state a P/E, so the rating's implications for earnings-based valuation cannot be assessed. This section is educational and does not constitute personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $28432.0M | $2212.0M | $1157000.0M | N/A | $1297.0M | $1939.0M | $12484.0M |
| FY 2024 | $25507.0M | $2146.0M | $0.0M | N/A | $1415.0M | $199.0M | $16416.0M |
| FY 2023 | $23231.0M | $1250.0M | $0.0M | N/A | $639.6M | N/A | $6523.3M |
Per the SEC financials, revenue rose from $23231.0M (FY 2023) to $28432.0M (FY 2025), while operating income moved from $1250.0M to $2212.0M over the same span. The FY 2025 net income figure of $1157000.0M is an outlier relative to operating income and is not reconciled in the source data; the FY 2024 and FY 2023 net income entries of $0.0M likewise do not reconcile. The market data reports an operating margin of 7.8%, a net margin of 68%, and a gross margin of 0%; these margin values are not internally consistent with the reported revenue and income lines and should be treated with caution. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with Debt/Equity at 1.16. Reported debt declined from $16416.0M (FY 2024) to $12484.0M (FY 2025), and cash rose from $199.0M to $1939.0M.
Recent Catalysts & News Wire Analysis
- RISK WATCH (RED): A headline reports a securities fraud probe following a 13% stock drop.
- MARKET WIRE (YELLOW): A PR Newswire item ties the 13% decline to disclosed product quality issues and an underway securities fraud investigation.
- MARKET WIRE (YELLOW): An Investing.com item reports a sale of $274.8 million in MDLN shares by GIC Private Ltd.
- MARKET WIRE (YELLOW): A Stock Titan item reports a 10% owner sale with a reported indirect position of 69.4M shares afterward.
- MARKET WIRE (YELLOW): A Seeking Alpha item carries the headline "Beware The Private Equity Overhang."
- MARKET WIRE (YELLOW): A Quiver Quantitative item reports $80,000 of lobbying disclosed.
The Butterfly Supply-Chain Graph reports no supply chain and no links or proprietary signals, so no proprietary supply-chain catalysts are available in the source data.
Open Questions
- What is the scope and status of the reported securities fraud investigation, and what product quality issues underlie the 13% decline?
- Why do the reported net income figures ($1157000.0M for FY 2025 and $0.0M for FY 2024 and FY 2023) fail to reconcile with operating income, and what are the correct EPS values?
- What are the company's principal products, customers, and revenue model?
- What is the terms and effect of the reported private equity overhang on float and share supply?
- What is the analyst consensus, price target range, and institutional 13F holder breakdown?
MDLN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Medline Inc. (MDLN) • Click "Debate This Headline" to argue it in the Roar Pit below
Seeking Alpha report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
PR Newswire report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
Quiver Quantitative report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Medline Inc. (MDLN) market action, institutional positioning, and fundamental catalysts.
MDLN Bull vs. Bear Conversation Board — What's Your Call at $32.12?
🔥 Official Bull vs. Bear Debate: Is MDLN (D • RQD 44/100) a Buy at $32.00?
Welcome to the MDLN (Medline Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on MDLN — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MDLN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Medline Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MDLN cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MDLN, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $32.00 (52-wk range $31.37 - $50.88), any beat on forward guidance forces shorts and underweight funds to chase.